Is Halozyme Therapeutics Inc (HALO) a risky stock?
As of July 29, 2026, Clavix grades Halozyme Therapeutics Inc (HALO) B+ for risk, a composite score of 79 out of 100 on an A+ to F scale, which puts HALO in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 29, 2026. Clavix regrades every trading day.
The five risk dimensions behind HALO's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how HALO scores on each, as of July 29, 2026.
What's moving HALO's risk right now
Company-specific signals Clavix flags behind HALO's current grade, drawn from recent news and filings as of July 29, 2026.
The deal adds another ENHANZE licensing partner, potentially bringing Halozyme upfront cash, development/commercial milestones, and tiered royalties on a successfully commercializ…
Halozyme Therapeutics is at a new high on Friday with earnings due on Aug. 6. Philip Morris International and KeyCorp are also at highs. The post Four Stocks Hit New Highs Amid Te…
The deal adds another ENHANZE-platform partnership to Halozyme's roster with a reputable biopharma counterparty, expanding potential future milestone and royalty revenue streams,…
Recent HALO news
The latest headlines Clavix ingested for Halozyme Therapeutics Inc, newest first. These feed the news-sentiment dimension of HALO's grade.
-
Halozyme Therapeutics (NASDAQ: HALO), a $9.72 billion biotech firm specializing in enzyme-based drug delivery technology, reported 42.2% revenue growth and trades near its 52-week high of $81.93. The company has strategic partnerships with Pfizer, Roche, and Bristol Myers Squibb, and analysts hold a unanimously positive outlook with 6 buys and 3 holds.
What a B+ grade means
On the Clavix A+ to F scale, HALO's composite of 79 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell HALO or any security. Grades are risk indicators, not predictions of return. Data may be delayed.